M. Pulido
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Advanced Breast Cancer Therapies 4
- Sarcoma Diagnosis and Treatment 3
- Oncology 9
- Cancer Treatment and Pharmacology 3
- CAR-T cell therapy research 3
- Co-authors
- Maud Toulmonde (5 shared papers)Emmanuelle Bompas (4 shared papers)Antoîne Italiano (6 shared papers)Jean‐Yves Blay (5 shared papers)Catherine Sautès‐Fridman (2 shared papers)François Bertucci (2 shared papers)Alban Bessede (4 shared papers)François Le Loarer (2 shared papers)
In The Last Decade
M. Pulido
16 papers receiving 419 citations
M. Pulido's Hit Papers
Peers
Comparison fields: 5 of 55
- Oncology 207
- Hepatology 50
- Pulmonary and Respiratory Medicine 155
- Immunology 100
- Cancer Research 33
Countries citing papers authored by M. Pulido
This map shows the geographic impact of M. Pulido's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pulido with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pulido more than expected).
Fields of papers citing papers by M. Pulido
This network shows the impact of papers produced by M. Pulido. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pulido. The network helps show where M. Pulido may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Pulido, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort Hit paper breakdown → | 2022 | 169 |
| 2 | 2019 | 120 | |
| 3 | 2012 | 57 | |
| 4 | 2023 | 27 | |
| 5 | 2018 | 13 | |
| 6 | 2010 | 7 | |
| 7 | 2010 | 6 | |
| 8 | 2020 | 5 | |
| 9 | 2022 | 4 | |
| 10 | 2017 | 3 | |
| 11 | 2022 | 3 | |
| 12 | 2018 | 3 | |
| 13 | 2025 | 1 | |
| 14 | 2017 | 1 | |
| 15 | 2022 | 1 | |
| 16 | 2020 | 1 | |
| 17 | 2020 | 0 |
About M. Pulido
M. Pulido is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology and Epidemiology, having authored 17 papers that have together received 421 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (4 papers), Sarcoma Diagnosis and Treatment (3 papers), Cancer Treatment and Pharmacology (3 papers), CAR-T cell therapy research (3 papers), Neuroendocrine Tumor Research Advances (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (1 paper), Virus-based gene therapy research (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Oncology (207 citations), Hepatology (50 citations), Pulmonary and Respiratory Medicine (155 citations), Immunology (100 citations) and Cancer Research (33 citations). M. Pulido has collaborated with scholars based in France, Spain and Colombia. Frequent co-authors include Maud Toulmonde, Emmanuelle Bompas, Antoîne Italiano, Jean‐Yves Blay, Catherine Sautès‐Fridman, François Bertucci, Alban Bessede, François Le Loarer, Michèle Kind and Nicolas Penel. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Nature Medicine, Current Opinion in Plant Biology and British journal of surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.